BrINGING nEW pOSSIBILITIES tO sYSTEMIC aMYLOIDOSIS

Attralus is developing novel pan-amyloid removal (PAR) therapeutics that directly bind to and remove toxic amyloid, opening the potential to treat and reverse disease in all types of systemic amyloidosis.

Amyloid Removal

Patient Diagnosis

All Disease Types

Unmet Medical Needs

Patients are in need of new treatment options

Systemic amyloidosis includes a diverse group of debilitating, progressive, and often fatal diseases, characterized by the accumulation of amyloid in vital organs.

OUR PIPELINE will TRANSFORM THE TREATMENT PARADIGM

Pan-amyloid removal offers a game-changing approach

Attralus is developing novel pan-amyloid removal (PAR) therapeutics that are designed to eliminate toxic, disease-causing amyloid in organs and tissues of patients with systemic amyloidosis.

Our proprietary technology has enabled us to develop novel biologics, as well as the world’s first amyloidosis-specific imaging agent that propel our strategy to identify and treat all stages and types of patients with this life-threatening disease. We aim to transform the treatment paradigm with disease-modifying amyloid removal — going beyond current treatments that slow progression, but do not remove amyloid from organs.

Background image of South San Francisco

About Attralus

Our Team & Mission

Our mission at Attralus is to improve the lives of patients with systemic amyloidosis by developing transformational therapeutics that remove toxic amyloid.  Our pan-amyloid removal (PAR) approach targets the underlying disease in all types of systemic amyloidosis, offering the potential to improve treatment outcomes for patients.

RECENT news

Press Releases
Attralus to Present at Piper Sandler 33rd Annual Virtual Healthcare ConferenceAttralus to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Nov 22, 2021
Attralus to Present New Data at 2021 American Society of Hematology Annual MeetingAttralus to Present New Data at 2021 American Society of Hematology Annual Meeting
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Nov 4, 2021
Attralus Closes $116 Million Series B FinancingAttralus Closes $116 Million Series B Financing
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Sep 8, 2021

our apologies

TABLET & MOBILE EXPERIENCES
ARE STILL UNDER CONSTRUCTION

Please view on a desktop or laptop computer.
close button😔

Attralus Job

AD/Director, Program Management
Attralus, Inc., (formerly Aurora Bio) is a VC funded privately held development stage biotechnology company focused on improving the lives of systemic amyloidosis patients, through the development of novel diagnostics and therapeutics...
Read More

AD/Director, Program Management

<< Back

Overview

Attralus, Inc., (formerly Aurora Bio) is a VC funded privately held development stage biotechnology company focused on improving the lives of systemic amyloidosis patients, through the development of novel diagnostics and therapeutics. We are developing pan-amyloid targeting agents that facilitate diagnosis, and the development of novel immunotherapies designed to clear amyloid fibrils in patients with systemic amyloid diseases. We aim to improve the diagnosis and treatment of systemic amyloid diseases, such as light chain (AL), transthyretin (ATTR), and LECT2 amyloidosis, to increase patient survival and quality of life.

Attralus’ technology has broad applications and the potential to address up to 30 systemic amyloid based diseases.  Attralus has a diagnostic imaging agent currently in a ph 1/2 trial, positioned to potentially be the first approved diagnostic specifically for amyloidosis. The company also has 2 novel therapeutic fusion proteins, directed at amyloid removal, that are in pre-clinical development

Headquartered in South San Francisco and founded in 2019, Attralus has recently completed a Series A funding with VenBio to carry forward its mission to improve the lives of systemic amyloidosis patients

Description

The AD/Director, Program Management will be responsible for providing both strategic and hands-on program and project management expertise. Initially reporting directly to the CEO, the AD/Director will be responsible for creating the program plan and budget and providing daily coordination and tracking of critical activities, assuring all milestones and deliverables are met. The Director will be responsible for developing the program management processes and procedures for the company, determining appropriate software and other tools, structuring regular meetings and communication within the company and with external collaborators.

Responsibilities

Collaborate with the management team to provide project management leadership and execution activities within the company and between external partners and Attralus teams.

Develop and execute integrated cross-functional project plans with established goals, milestones, timelines and budget, with a key focus on bringing pre-clinical therapeutic programs into early clinical development

Conduct and direct day-to-day program activities to meet milestones; monitoring critical path activities to ensure delivery of program objectives.

Drive planning for key drug development milestones.

Maintain effective communication with the management team through oral and written correspondence and ensure adequate documentation of each communication. 

Always use/model/maintain/promote best practices in Program Management, including the use of agendas, minutes, dashboards, maintain document repository, establish and implement templates, tools, and processes to drive efficiency, alignment, communication, and effective planning.

Create and maintain easily accessible, high level program documents in electronic format. 

Recommend, manage and train on necessary software and tools.

Identify, develop and/or maintain an appropriate electronic platform (SharePoint, Shared Folders, etc.) for reporting/archiving/documentation of relevant program information, records, etc. 

Conduct risk management, contingency and scenario planning using appropriate program management tools.

Identify program issues or resource gaps and facilitate resolution.

Communicate program information and support development of program presentations to senior leadership, board members, investors and other key stakeholders as appropriate.

Contribute to budgetary planning at the program level.

Facilitate adherence to Aurora’s governance processes; work with key stakeholders to prepare for those interactions; lead/support as appropriate. Ensure implementation of governance decisions.

Qualifications

Minimum of a BA/BS in a scientific disciplined is required, Advance degree preferred

7+ years of program management or equivalent experience in a pharmaceutical or biotechnology organization.

Experience with research/pre-clinical and early clinical development project planning required. PM Certification is a plus.

Rare disease experience a strong plus (not required).

Desire and ability to work in a start-up, fast paced organization where you will wear many hats.

Must have excellent verbal and written communication skills as well as exceptional organizational capability.

Ability to drive program plans and timelines (across multiple functional areas) is essential.  Proven success in goal setting, prioritization and time management is required.

Understanding of FDA and/or EMA quality and regulatory processes. Prior experience with regulatory filings is desirable. 

Experience working with external partners is desirable.

Ability to work independently in decision-making and resolution of program obstacles and conflicts.

Familiarity with developing budgets and forecasting is desirable.

Ability to function autonomously, with an appreciation of detail while being cognizant of “the big picture.”

Have a patient-first mindset. All decisions made with patients in mind.

Proficiency with Microsoft Word, Excel, PowerPoint, and Project is required.

Benefits/Equal Opportunity Employer

Attralus, Inc. offers both comprehensive benefits and Paid Time Off (PTO) plans for employees, which begin on the first day of employment.

Attralus, Inc. is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.